Vaderis Raises $152 Million and Starts HEROIC

Company: Vaderis Therapeutics · Event Type: Deal and Financing · Product/Asset: engasertib · Subject: Hereditary Hemorrhagic Telangiectasia · Event Date: August 11, 2026 Summary Vaderis Therapeutics closed an oversubscribed $152 million Series B and announced initiation of the global Phase 3 HEROIC study of engasertib…